Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy in rheumatoid arthritis.

Y P Goekoop1, C F Allaart, F C Breedveld

  • 1Department of Rheumatology, Vr&OV0451;e Universiteit Medical Center, Amsterdam, The Netherlands.

Current Opinion in Rheumatology
|May 3, 2001
PubMed
Summary

Early rheumatoid arthritis suppression is key to preventing joint damage. Combination therapies, like methotrexate with other disease-modifying antirheumatic drugs or biologic agents, show promise over monotherapy for managing rheumatoid arthritis disease activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis.

Seminars in arthritis and rheumatism·2025
Same author

Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis.

Seminars in arthritis and rheumatism·2023
Same author

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.

Annals of the rheumatic diseases·2022
Same author

Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort.

Scandinavian journal of rheumatology·2022
Same author

No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis.

Pediatric rheumatology online journal·2019
Same author

Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.

Arthritis research & therapy·2019

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Early suppression of rheumatoid arthritis (RA) disease activity is crucial for preventing joint destruction and functional decline.
  • Aggressive treatment strategies, including combination therapies, are increasingly advocated by rheumatologists for RA management.
  • Methotrexate (MTX) is a cornerstone in RA treatment, often used in combination regimens.

Purpose of the Study:

  • To review the current evidence on combination therapy for rheumatoid arthritis.
  • To compare the efficacy of combination treatment strategies versus monotherapy in RA patients.
  • To identify gaps in knowledge regarding optimal RA treatment strategies.

Main Methods:

  • Literature review of recent studies on RA combination therapy.

Related Experiment Videos

  • Analysis of clinical trial data comparing combination therapy with monotherapy.
  • Evaluation of studies focusing on treatment strategies rather than solely drug combinations.

    • Main Results:

    • Combination therapy of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone demonstrated superior benefits over monotherapy in early RA.
    • Combination therapy with novel tumor necrosis factor-alpha (TNF-α) blocking agents plus methotrexate shows promise in chronic RA.
    • Current research primarily focuses on the efficacy of drug combinations, not comprehensive treatment strategies.

    Conclusions:

    • Combination therapies offer significant advantages in managing rheumatoid arthritis disease activity.
    • Further research is needed to evaluate different treatment strategies and optimize RA management.
    • Unanswered questions remain regarding the long-term efficacy and optimal sequencing of combination therapies in RA.